



A Message from the

This year, we are more than halfway to **Breast Cancer Deadline 2020**[®] – the National Breast Cancer Coalition's (NBCC) campaign to know how to end breast cancer by January 1, 2020.

resident

When we set the Deadline in 2010, NBCC made a bold and risky commitment. We have never shied away from taking risks or thinking big. We have never grown comfortable or become complacent because of our many successes. The stakes are just too high complacency costs lives; more than 40,000 women and 400 men die of breast cancer every year in this country alone; more than half a million women worldwide. We cannot allow that to continue.

This year, with your support, we made progress and overcame challenges to our goal of knowing how to end breast cancer. Our Artemis Project® participants met again to discuss our two areas of focus—primary prevention of breast cancer and preventing metastasis and took steps toward developing clinical trials in 2017. We trained dozens more advocate leaders in the science of breast cancer at our Project LEAD® Institute and more than a hundred advocates from all over the country learned advocacy and leadership skills at our thirdannual Advocate Leadership Summit in Washington, D.C.

We also beat back a challenge to the Department of Defense Breast Cancer Research Program (DoD BCRP), which was threatened during the annual Congressional appropriations process in the summer of 2015. With NBCC's National Action Network, we prevailed in preserving the funding for this groundbreaking program that supports unconventional approaches that might provide important breakthroughs. We will remain vigilant to protect the DoD BCRP, which was first established as a direct result of NBCC advocacy.

NBCC 2015 ANNUAL REPORT

In the year ahead, we must raise more funds to reach the \$150 million target we set as the budget for **Breast Cancer Deadline 2020**[®]. We must also continue our efforts to ensure that the DoD BCRP continues and that the funding is used to answer important questions. We must get the Accelerating the End of Breast Cancer Act enacted into law. And we must continue to train advocate leaders who can take a place at the table to help make breast cancer research decisions.

2

2015 was a year of great progress for NBCC, but a lot of work remains to be done. The task ahead is daunting, but that challenge won't stop NBCC. When you consider what we, together, have already accomplished, we know that this ambitious goal can be achieved. How do we know we can do it? Because since its inception, NBCC has been the undeniable leader in identifying and marshalling the policy, scientific, clinical and research tools needed to end breast cancer.

With your continued support and action, NBCC will achieve our goal of knowing how to end breast cancer by 2020.

Fran Visco President, National Breast Cancer Coalition

Leadership is key to ending breast cancer. In 2015, NBCC continued to train women and men from the U.S. and internationally to advance our mission.

PROJECT LEAD[®]: NBCC'S UNPRECEDENTED SCIENCE TRAINING FOR THE PUBLIC

Training

NBCC held a Project LEAD® Institute in July 2015. The Project LEAD® Institute is our most intensive science course and trains advocates in cancer biology, genetics, DNA, RNA, proteins, epidemiology, clinical trial research design and much more. This is a sixday program, based on adult learning principles, with a stellar faculty and veteran mentors who guide graduates for a year following the course. The July 2015 course included 52 students from 22 states and four countries.

2015 LEADCASTS

vocate

In addition, NBCC held two LEADCasts during 2015. In March Alana Welm, PhD, University of Utah, lead a presentation on Breast Cancer Metastasis: Are We Making Progress? Dr. Welm presented an analysis of the status of research in breast cancer metastasis and highlighted the work being done on the Artemis Project on understanding and stopping metastasis. In October Steve Shak, MD, Genomic Health, presented results of the Tailorx study. This study included significant NBCC advocate involvement, was designed and conducted by ECOG-ACRIN and sponsored by the National Cancer Institute. The study demonstrated that 99% of women with low Oncotype DX[®] Recurrence Score® results of 10 or less who received hormonal therapy alone without chemotherapy had less than a one percent chance of distant recurrence at five years.





2015 ADVOCATE LEADERSHIP SUMMIT, WASHINGTON D.C.

We convened our third Advocate Leadership Summit in Washington, D.C. May 2 – May 4, 2015. The Summit offered plenary and workshop sessions on the latest information about breast cancer research, public policy and quality health care. Leading scholars, researchers and experts in their fields attended the Summit to present cutting-edge research and relevant controversies. A sample of the sessions, along with the presenters included:

NBCC 2015 ANNUAL REPORT

An Armchair Conversation: How Far Have We Come With The Artemis Project[®] And What's Next?

Silvia Formenti, MD, Weill Cornell Medical College; *Frank Calzone, PhD,* Biotechnology Consultant

Immunology: The Next Big Trend or the Real Thing?

Silvia Formenti, MD, Weill Cornell Medical College; *Leisha Emens, MD, PhD,* Johns Hopkins University School of Medicine; *Stephanie Goff, MD,* Surgery Branch, National Cancer Institute

A Story: How a Concept Gets to a Clinic in Your Neighborhood

Barney Graham, MD, PhD, Vaccine Research Center, NIAID; James Gulley, MD, PhD, Genitourinary Malignancies Branch, Center for Cancer Research, NCI;

John Schiller, PhD, Neoplastic Disease Section, Laboratory of Cellular Oncology, Center for Cancer Research, NCI

Big Data, Intellectual Property and Open Source Sharing: What Does it All Mean for Ending Breast Cancer?

 Robert Cook-Deegan, MD, Institute for Genome Sciences and Policy, Duke University;
Aled Edwards, PhD, Structural Genomics Consortium and University of Toronto;
Susan Love, MD, MBA, Dr. Susan Love Research Foundation

We enable the attendees to return to their communities ready to carry out the work of NBCC and **Breast Cancer Deadline 2020**[®].

Accelerating Innovation in

We expanded the group of scientists and advocates working on the **Artemis Project**[®], broadening the disciplines, perspectives and institutions fueling this effort. In March, we held the annual meetings of both Artemis Projects[®] (primary prevention and preventing metastasis).

esearc

PRIMARY PREVENTION— PREVENTIVE VACCINE PROJECT

The primary goal of the 2015 annual meeting was to identify the protein targets within breast tumor cells that can be used to develop a preventive breast cancer vaccine for healthy women. A second goal was to further develop a strategic plan for vaccine creation and clinical trial development to enable the initiation of a clinical trial by 2017. At the end of the two-and-a-half day meeting, participants selected six protein targets to be incorporated into a new vaccine, developed a strategy with milestones to create and test this vaccine and established a timetable to accelerate the process.

PREVENTION OF METASTASIS PROJECT

Based on discussions at the annual meeting, it was determined that a second Artemis Project[®] would focus on tumor dormancy and the immune system. Since that meeting, a group of Artemis participants have begun testing how the immune system interacts with dormant disseminated tumor cells; those cells that migrate from the primary tumor site.

CLINICAL TRIALS

We have continued to play an important role in the EMBRACA Trial to test a first in class PARP inhibitor in women with metastatic breast cancer and the BRCA mutation. Our U.S. Project LEAD[®] advocates worked on the Protocols Committee, the Data Safety Monitoring Board, have reviewed and edited educational materials and have conducted national education and outreach for the trial. We have also helped connect international advocates to the EMBRACA trial efforts in many of the countries where sites have been newly established.

to Save Lives

As a result of NBCC's grassroots advocacy, the Department of Defense Breast Cancer Research Program (DOD BCRP) was created in 1992 to "eradicate breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers." NBCC's advocacy has brought about more than \$3 billion for the worldwide research community through the DOD budget alone.

Resources


Congressional support and funding for the DOD BCRP remains strong even after a significant challenge in the summer of 2015 that would have essentially eliminated the program. NBCC advocates were critical to ensuring that the challenge was not successful. Immediately after getting word that the program was being challenged, NBCC mobilized our National Action Network, our most enthusiastic and responsive grassroots advocates, to flood Senate offices with messages urging them to vote against the effort to destroy this important program. We continue to fight for funding for this program through the Congressional appropriations process, but know that we may experience significant threats towards the program in the coming year.

Leveraging Government

LOBBY DAY 2015

In May of 2015, NBCC hosted a Lobby Day where advocates from across the country visited Congressional offices and used social media to advance **Breast Cancer Deadline 2020**[®], increase cosponsor support for our landmark legislation, the Accelerating the End of Breast Cancer Act (AEBCA) and urge continued support for the DOD BCRP. NBCC's grassroots efforts grew bipartisan support for our legislation with House and Senate cosponsors. Further, the lobbying efforts resulted in Congress passing a funding bill that included \$120 million for the DOD BCRP.





President's

The President's Council is a national network of like-minded women and men who provide the leadership and financial support to the National Breast Cancer Coalition Fund in our mission to end breast cancer. Our President's Council members are key ambassadors, reaching into their own communities and networks on our behalf.

Eliza Adams Terrv K. Adams Madeline and Stephen Anbinder Amy L. Applebaum Susan and Robert Appleton Annette and Avram Bar-Cohen Carol A. Beagan Lori and Bob Beck Isabelle T. Bisceglio Carmella Bocchino Phyllis Bocian Donna Brogan Judy Bernstein Bunzl and Stephen Bunzl Maureen Calloway Carnevale and **Richard Carnevale** Chris and Delburn Carpenter Carol and Richard Chadakoff Diane and Alan Chase Jane Clark Jan R. Cloyde Mary Ellen Colten Elaine M. Coughlin Susan M. Dacks Doreen and Robert Davis Judy Dering and Frank Calzone Kay Dickersin and Robert Van Wesep Betty J. Dietrich Elaine M. Dornig Donna Duncan Kate Dwyer Dale and Harry Eastman N. Beth Emery Ileane and Irvin Fagin Sherri Ades Falchuk

NBCC 2015 ANNUAL REPORT

Phyllis Fern Elizabeth and Richard Frank Ellen Frankel Patricia L. Freysinger Judith K. Gain Dorian S. Goldman and Marvin Israelow Sherry Goldman Stephanie and Josh Goldstine Pennelope Goodfriend George Grant Gabrielle and Rob Greenberg Marcy Gringlas Kathleen and Arthur Harris Ann Harris Pat Haugen Susan R. Hester Giselle Hicks and William Ross Ira Hillman and Jeremy Barber Judi J. Hirshfield-Bartek and Elmer Bartek Laura A. Honnold Jean L. Jorgenson Judy M. Judd Hugh Kendrick Amanda Knisely-Medina Elaine Koenigsberg Nancy Krakaur Robert K. Kretzman Harvey D. Kushner Diane Senica Langley Leona Laskin Christina Leu Paula Levine Susan Love

Ngina Lythcott and Byllye Avery Maria W. Lyzen Mary Matyka Michele May and David Walt Musa and Tom Mayer Carolyn C. McCormick Molly Mead Christine M. Millen Stephen Moeller Gayle A. Nobbs Christine and Dermod Norton John Noss Norma and Norman Nutman Jane Perlmutter Harry L. Peterzell Michele Rakoff and Alan Sieroty Rosemary Rosso Maria P. Ruffilli Elizabeth H. Schulte Gail and Steven Shak **Russell Silverman** Arleen F. Sorkin and Christopher Lloyd Sandra L. Spivey **Elaine Stokes** Nicki and Harold Tanner Marcia Taylor Fran M. Visco and Arthur N. Brandolph Carol and Terry Wall Sandra Walsh Ann C. Yahner Kim Zehr

8

INDIVIDUAL

2015

\$20,000 AND ABOVE George Grant Musa and Tom Mayer Christine and Dermod Norton Steve Tisch Family Foundation

\$10,000 TO \$19,999

Anonymous Amy Bonoff and Harris Jaffe Joyce Brandman Kate Dwyer Silvia C. Formenti Patricia L. Freysinger Marvin Jubas Liane M. Lindner Michele May and David Walt Michele Rakoff and Alan Sieroty Gaia Samore Arleen F. Sorkin and Christopher Lloyd Flaine Stokes Fern and Lenard Tessler Carol and Terry Wall Ann C. Yahner Richard S. Ziman

\$5,000 TO \$9,999

Terry K. Adams Kathy Ball Lori and Bob Beck Susan V. Bershad Judy Bernstein Bunzl and Stephen Bunzl Debbie and James Burrows Alec Call and Bryan Johns Ellen Caplan Glen Charles John Esformes Rachel Feder Alice and Lawrence Friedland Armando Giuliano Patricia L. Glaser Sherry Goldman Dorian S. Goldman and Marvin Israelow Pennelope Goodfriend William H. Isacoff Susan K. Johns Blake Johns and Brittany Shaw Michael S. Kurtz Karen and Chuck Lorre

NBCC 2015 ANNUAL REPORT

Susan Love John Noss Harry L. Peterzell Bill Resnick Linda and Ken Rothweiler Kenneth L. Stein Fran M. Visco and Arthur N. Brandolph

JONOTS

\$2,500 TO \$4,999

Barbara and Todd Albert Madeline and Stephen Anbinder Amy L. Applebaum Debbie and Mark Attanasio Gerry Bernardi and Joe Keenan John Bernbach Lucile K. Billett Daniel Bonoff Carol and Richard Chadakoff Jane Clark Vicky Cooke Doreen and Robert Davis Judy Dering and Frank Calzone Kay Dickersin and Robert Van Wesep Donna Duncan Marcy Gringlas Kathleen and Arthur Harris Alison Hersh Marjorie and Jeffrey Honickman Russell M. Kern Daniel Klein Amanda Knisely-Medina Elaine Koenigsberg David C. Lee Carolyn C. McCormick Beth McCoy Andy Miller Brian Norris David Pons Annette Shapiro Stephanie Sperber Karen Tarte Marcia Taylor Jeffrey Tranen Peter Weil Daphna Ziman

CORPORATE / ORGANIZATIONS

\$250,000 AND ABOVE Joyce and Irving Goldman Family Foundation National Philanthropic Trust Vance Wall Foundation

\$100,000 TO \$249,999

BioMarin Pharmaceutical Inc. Cancer International Research Group Judges & Lawyers Breast Cancer Alert Pfizer Inc.

\$50,000 TO \$99,999

Amgen Celgene Entertainment Industry Foundation iS Clinical by Innovative Skincare Revlon Time Warner, Inc.

\$25,000 TO \$49,999

Cancer Treatment Centers of America Eli Lilly and Company Corporate Affairs , LLC Genentech, Inc. Longchamp USA, Inc. Novartis Oncology Skadden, Arps, Slate, Meagher & Flom LLP

\$10,000 TO \$24,999

Able Equipment Rental Inc. Alamo Breast Cancer Foundation BET Holdings Catholic Community Foundation Citigroup Global Market, Inc. Classique Cozen O'Connor Genomic Health, Inc. Hearst Magazines Joseph F. Walsh and Marjorie Walsh Foundation JWT KPMG, LLP Linear Technology Corporation

M & M Retail Luxury

Consulting Inc Mellam Family Foundation Milbank, Tweed, Hadley & McCloy LLP Oticon, Inc. Schwab Charitable Fund The Bruce Cohen Memorial Cancer Foundation Translational Research in Oncology-US, Inc. (TRIO-US)

\$5,000 TO \$9,999

Amarillo College of Hairdressing, Inc. AR New York Barbara Silver Levin Foundation **California Teachers** Association Casey 1995 Trust Forest Laboratories, Inc. **Glickfield Family Foundation Kayne Foundation** Kirkland and Ellis Foundation MediaCom Norton & Barbara Mandel **Family Foundation Robert & Shirley Harris Family Foundation** Showtime Networks, Inc. The Bill Bernbach Foundation The David Geffen Foundation

\$2,500 TO \$4,999

Aon Foundation **Breslow Family Foundation Brooks Brothers CARE** Advocates Cedar Sinai Breast Center Central Brooklyn Ascend **Charter School** Chris's Stuff, Inc. HSNi LLC Insight Cosmetics Group Jackson Lewis P.C. Kayne Anderson Capital Advisors Foundation Lisa Hoffman Beauty LLC Match.com, LLC Northern Trust **ReFinery 29** St. Louis Breast Cancer Coalition The Viola Fund

9

NATIONAL BREAST CANCER COALITION BOARD OF DIRECTORS

Boards

Director: Bonnie Anderson After Breast Cancer Diagnosis (ABCD) Alternate: Ginny Finn

2015

Director: Christine Carpenter Cedar Valley Cancer Committee: Beyond Pink Team Alternate: Lori Seawel

Director: Victoria Cooke (Vicky) Delaware Breast Cancer Coalition, Inc. Alternate: Rena Howard

Director: Mary Lynn Faunda Donovan St. Louis Breast Cancer Coalition Alternate: Sue Baebler

Director: Donna Duncan Linda Creed Breast Cancer.org Alternate: Linda Camerota

Director: Ruth Eldredge Georgia Breast Cancer Coalition Fund Alternate: Amy Upchurch

Director: Michelle Esser Young Survival Coalition Alternate: Joy Simha

Director: Ivis Febus-Sampayo SHARE Alternate: Helen Schiff

Director: Ann Fonfa Annie Appleseed Project Alternate: Tracy Leduc

Director: Sherry Goldman Cedars Sinai Breast Center Alternate: Sylvia Estrada

Director: Patricia Haugen Inflammatory Breast Cancer Research Foundation Alternate: Ginny Mason

Director: Debbie Hayes Virginia Breast Cancer Foundation Alternate: Lisa Branner Stickley

Director: Judi Hirshfield-Bartek Dr. Susan Love Research Foundation Alternate: Heather Cooper Ortner

NBCC 2015 ANNUAL REPORT

Director: Marlene McCarthy Rhode Island Breast Cancer Coalition Alternate: Jean Albert

Director: Shirley Mertz Metastatic Breast Cancer Network Alternate: Ginny Knackmuhs

Director: Christine Norton Minnesota Breast Cancer Coalition

Director: Cindy Pearson National Women's Health Network

Director: Rose Marie Sitko Michigan Breast Cancer Coalition Alternate: Sherri Richards

Director: Vacant Nueva Vida Alternate: Gloria Elliott

Director: Frances M. Visco National Breast Cancer Coalition

Director: Sandy Walsh CABCO Alternate: Michele Rakoff

Director: Gretchen Walton Breast Health Collaborative of Texas Alternate: Rhonda Turner

Director: Jerry Worden Alamo Breast Cancer Foundation Alternate: Beth Emery

NATIONAL BREAST CANCER COALITION FUND BOARD OF TRUSTEES

Dorian S. Goldman Sherry Goldman, RN, NP, MSN Judi Hirshfield-Bartek, RN, MS, OCN Liane M. Linder Christine K. Norton Michele Rakoff Linda A. Rothweiler, DMD Dennis Slamon, MD, Ph.D Frances M. Visco, J.D. Carol Vance Wall

Organization for identification purposes only

10



The **National Breast Cancer Coalition Fund** is a 501(c)(3) entity that designs and runs programs to educate, train, and inform advocates, policy makers, scientists, providers, and the public about science, health care and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all, and gives a powerful, effective voice to breast cancer advocates everywhere.

The **National Breast Cancer Coalition** is a 501(c)(4) organization that designs and works to enact legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.

National Breast Cancer Coalition, 1010 Vermont Ave., NW, Suite 900 Washington, DC 20005

BreastCancerDeadline2020.org